HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $15
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $15.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $15.